Quest Partners LLC Acquires Shares of 10,918 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Quest Partners LLC acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 10,918 shares of the company’s stock, valued at approximately $197,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PHAT. Huntington National Bank increased its holdings in Phathom Pharmaceuticals by 62.2% in the third quarter. Huntington National Bank now owns 1,471 shares of the company’s stock valued at $27,000 after buying an additional 564 shares during the last quarter. Chartwell Investment Partners LLC purchased a new position in Phathom Pharmaceuticals in the third quarter valued at $396,000. US Bancorp DE increased its holdings in Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock valued at $95,000 after buying an additional 1,166 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Phathom Pharmaceuticals by 91.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,134 shares of the company’s stock valued at $237,000 after buying an additional 6,257 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Phathom Pharmaceuticals by 41.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock valued at $43,000 after buying an additional 722 shares during the last quarter. Institutional investors and hedge funds own 99.01% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. The Goldman Sachs Group increased their target price on Phathom Pharmaceuticals from $10.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, September 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Monday, August 12th.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT opened at $8.97 on Thursday. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $6.07 and a fifty-two week high of $19.71. The company has a market capitalization of $613.34 million, a price-to-earnings ratio of -1.58 and a beta of 0.72. The firm has a 50-day simple moving average of $15.06 and a 200-day simple moving average of $13.31.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.